We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Method Detects Kidney Cancer Biomarkers in Urine

By LabMedica International staff writers
Posted on 24 Dec 2012
A rapid and inexpensive method using bioplasmonic paper was developed for detecting biomarkers of kidney cancer in urine.

Two biomarkers are present in elevated amounts in the urine of patients with kidney cancer, aquaporin-1 and adipophilin. More...
A team of scientists created what they call bioplasmonic paper—filter paper impregnated with gold nanorods linked to antibodies that would bind to aquaporin-1. Gold nanorods respond to light by producing localized surface plasmon resonance (LSPR), a specific type of light emission that involves waves of electrons moving across the surface of metal nanostructures. LSPR is very sensitive to molecular events that occur on or near the surface of the particles, including binding of bimolecules to attached antibodies.

Traditionally, LSPR detection devices are rigid, flat surfaces such as glass, but Dr. Srikanth Singamaneni from the department of mechanical engineering and the Siteman Cancer Center at Washington University (St Louis, MO, USA) and colleagues demonstrated that standard filter paper can also serve as an LSPR substrate. The team found that the sensitivity and limit of detection for the paper-based system is at least as good, if not better, than for conventional rigid substrates. In this case, the limit of detection matched that of the range of aquaporin-1 levels in patients with kidney cancer. Other advantages of using paper include its wicking properties, flexible surface for collection, compatibility with standard ink jet printing technology, low cost, and ease of disposal.

The findings were published online on October 25, 2012, in the journal Analytical Chemistry.

Currently, the technology used clinically to detect specific proteins such as the two kidney cancer biomarkers, known as an enzyme-linked immunosorbent assay (ELISA), is both expensive and time-consuming, and requires a relatively high level of laboratory expertise to produce accurate results.

Related Links:

Washington University




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.